Sector News

Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology

June 13, 2019
Life sciences

Rare diseases specialist Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.

The drugmaker said on Wednesday it would buy a newly established company owning the drug candidate for the treatment of primary haemophagocytic lymphohistiocytosis (HLH), and related assets, for 4.9 billion crowns ($519 mln).

HTH is a rare life-threatening condition in which the immune system attacks tissues and organs, mainly in young children.

Sobi signed an exclusive license agreement in 2018 with Swiss company Novimmune for the rights to emapalumab, with an option to buy all assets at a later stage.

Sobi said the refocusing of its research and development operations, at a cost of 100–200 million crowns in 2019, would lead to annual savings of 200–300 million from 2020 that would allow it to invest more in late-stage development projects.

“This planned structural alignment will sharpen the focus of the company on our two main areas: Hematology and Immunology. The integration of the emapalumab organization makes this alignment possible,” CEO Guido Oelkers said.

The rival to Roche, Novo Nordisk and Shire said it expected the acquisition, which is debt financed, to be earnings neutral in 2019.

It stuck to its target for a full-year profit before amortization of 5.0-5.3 billion crowns on sales of 12.5-13.0 billion.

By Anna Ringstrom

Source: Reuters

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.